KeyPath MRSA/MSSA Blood Culture Test
MicroPhage's KeyPath, the only blood culture test to have gained FDA clearance to report accelerated antibiotic susceptibility results, provides physicians with a tool for selecting safer and more effective therapy. Results are available much sooner than is typically practiced, shortening the time to antibiotic susceptibility results from three days to one. The KeyPath test platform incorporates MicroPhage's proprietary Bacteriophage Amplification Technology (BAT) to create a simple-to-use, instrument-free test platform that empowers clinical laboratories of any size or means to deliver KeyPath benefits to its physicians and patients. Recently MicroPhage initiated clinical trials to further expand product claims for KeyPath and increase accessibility to more than 90% of U.S. hospitals.
Ad Statistics
Times Displayed: 22687
Times Visited: 478 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Survey Methodology
Kinesis Survey Technologies conducted the online survey. Respondents were recruited by via email between October 1 and October 8, 2012, from a nationwide list of medical professionals involved in infectious disease diagnosis and treatment at major hospitals and reference laboratories in the U.S. In addition to infection control specialists and laboratorians, the survey sample included hospitalists, pharmacists, infectious disease specialists and hospital administrators. As an incentive for completion, a contribution was made to Doctors without Borders for each completed survey. The survey had an overall completion rate of 3%.
About MicroPhage
Based in Longmont, Colorado, privately held MicroPhage, Inc. develops easy-to-use diagnostic tests for accelerated bacterial identification and antibiotic susceptibility/resistance testing. As antibiotic resistance increases, early antibiotic susceptibility results are increasingly important to physicians in treating critically ill patients.
References
1 Kaye et al. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis (2008) vol. 46 (10) pp. 1568-77
2 Cosgrove SE et al, Comparison of Mortality Associated with Methicillin-Resistant and Methicillin- Susceptible Staphylococcus aureus Bacteremia: A Meta-analysis. Clinical Infectious Diseases 2003; 36:53-9.
Ed Stevens
Chase Communications
estevens@chasepr.com
727-412-1541
Back to HCB News
